213 related articles for article (PubMed ID: 18254013)
41. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis.
Black CJ; Burr NE; Camilleri M; Earnest DL; Quigley EM; Moayyedi P; Houghton LA; Ford AC
Gut; 2020 Jan; 69(1):74-82. PubMed ID: 30996042
[TBL] [Abstract][Full Text] [Related]
42. Herbal medicines for treatment of irritable bowel syndrome.
Liu JP; Yang M; Liu YX; Wei M; Grimsgaard S
Cochrane Database Syst Rev; 2006 Jan; (1):CD004116. PubMed ID: 16437473
[TBL] [Abstract][Full Text] [Related]
43. Irritable bowel syndrome in children: pathogenesis, diagnosis and evidence-based treatment.
Sandhu BK; Paul SP
World J Gastroenterol; 2014 May; 20(20):6013-23. PubMed ID: 24876724
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
Rahimi R; Nikfar S; Abdollahi M
Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
[TBL] [Abstract][Full Text] [Related]
45. Irritable bowel syndrome symptom severity improves equally with probiotic and placebo.
Lyra A; Hillilä M; Huttunen T; Männikkö S; Taalikka M; Tennilä J; Tarpila A; Lahtinen S; Ouwehand AC; Veijola L
World J Gastroenterol; 2016 Dec; 22(48):10631-10642. PubMed ID: 28082816
[TBL] [Abstract][Full Text] [Related]
46. Recommendations for pharmacological clinical trials in children with irritable bowel syndrome: the Rome foundation pediatric subcommittee on clinical trials.
Saps M; van Tilburg MA; Lavigne JV; Miranda A; Benninga MA; Taminiau JA; Di Lorenzo C
Neurogastroenterol Motil; 2016 Nov; 28(11):1619-1631. PubMed ID: 27477090
[TBL] [Abstract][Full Text] [Related]
47. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
[TBL] [Abstract][Full Text] [Related]
48. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial.
Cappello G; Spezzaferro M; Grossi L; Manzoli L; Marzio L
Dig Liver Dis; 2007 Jun; 39(6):530-6. PubMed ID: 17420159
[TBL] [Abstract][Full Text] [Related]
49. Side effects associated with pharmacotherapy for pediatric irritable bowel syndrome and functional abdominal pain - not otherwise specified: a systematic review.
Rexwinkel R; Zeevenhooven J; van Etten-Jamaludin FS; Benninga MA; Tabbers MM
Expert Opin Drug Saf; 2019 Feb; 18(2):111-125. PubMed ID: 30676113
[TBL] [Abstract][Full Text] [Related]
50. Psychological therapies for the management of chronic and recurrent pain in children and adolescents.
Eccleston C; Palermo TM; Williams AC; Lewandowski A; Morley S
Cochrane Database Syst Rev; 2009 Apr; (2):CD003968. PubMed ID: 19370592
[TBL] [Abstract][Full Text] [Related]
51. Peppermint Oil Treatment for Irritable Bowel Syndrome: A Randomized Placebo-Controlled Trial.
Nee J; Ballou S; Kelley JM; Kaptchuk TJ; Hirsch W; Katon J; Cheng V; Rangan V; Lembo A; Iturrino J
Am J Gastroenterol; 2021 Nov; 116(11):2279-2285. PubMed ID: 34319275
[TBL] [Abstract][Full Text] [Related]
52. Abdominal pain endpoints currently recommended by the FDA and EMA for adult patients with irritable bowel syndrome may not be reliable in children.
Saps M; Lavigne JV
Neurogastroenterol Motil; 2015 Jun; 27(6):849-55. PubMed ID: 25845918
[TBL] [Abstract][Full Text] [Related]
53. The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis.
Bosman M; Elsenbruch S; Corsetti M; Tack J; Simrén M; Winkens B; Boumans T; Masclee A; Keszthelyi D
Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):459-473. PubMed ID: 33765447
[TBL] [Abstract][Full Text] [Related]
54. Irritable bowel syndrome in children: the placebo response rate and influencing factors a meta-analysis.
Cai LL; Li X; Cai QH; Guo SX; Zhang Y; Sun WC; Zhao ZH; Hu SY
Pediatr Res; 2024 May; 95(6):1432-1440. PubMed ID: 38253876
[TBL] [Abstract][Full Text] [Related]
55. Management of faecal incontinence and constipation in adults with central neurological diseases.
Coggrave M; Norton C
Cochrane Database Syst Rev; 2013 Dec; (12):CD002115. PubMed ID: 24347087
[TBL] [Abstract][Full Text] [Related]
56. Interventions for recurrent idiopathic epistaxis (nosebleeds) in children.
Qureishi A; Burton MJ
Cochrane Database Syst Rev; 2012 Sep; (9):CD004461. PubMed ID: 22972071
[TBL] [Abstract][Full Text] [Related]
57. A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms.
Cash BD; Epstein MS; Shah SM
Dig Dis Sci; 2016 Feb; 61(2):560-71. PubMed ID: 26319955
[TBL] [Abstract][Full Text] [Related]
58. Managing irritable bowel syndrome in children.
Adams HL; Basude D; Kyle A; Sandmann S; Paul SP
Nurs Stand; 2016 Oct; 31(7):42-52. PubMed ID: 27762987
[TBL] [Abstract][Full Text] [Related]
59. Peppermint oil in irritable bowel syndrome.
Grigoleit HG; Grigoleit P
Phytomedicine; 2005 Aug; 12(8):601-6. PubMed ID: 16121521
[TBL] [Abstract][Full Text] [Related]
60. Pharmacological interventions for hypertension in children.
Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
Evid Based Child Health; 2014 Sep; 9(3):498-580. PubMed ID: 25236305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
